"An estimated one in eight American adults are taking GLP-1 (glucagonlike peptide 1) drugs including Wegovy and Zepbound to treat conditions such as diabetes or to lose weight. Some experts believe that some people will need to take these medications for life to retain their results. But research suggests most of these individuals will quit the drugsand when people do so, most of their weight tends to come back. The same is true for those who lose weight by dietingafter the diet ends, they typically regain the weight."
"Now a pair of independent clinical trials point to two possible methods for preventing weight regain: taking a daily oral GLP-1 drug called orforglipron or taking a supplement that contains a pasteurized strain of Akkermansia muciniphila bacteria. Both studies were published on Tuesday in the journal Nature Medicine. In the orforglipron study, which was funded by the drug's maker, Eli Lily, researchers conducted a controlled trial that followed more than 370 people who had been injecting either semaglutide or tirzepatide."
"After 72 weeks on one of these drugs, the participants switched to a daily orforglipron pill or a placebo. On supporting science journalism If you're enjoying this article, consider supporting our award-winning journalism by subscribing. By purchasing a subscription you are helping to ensure the future of impactful stories about the discoveries and ideas shaping our world today. After around a year, the participants who had gone on orforglipron tended to maintain more of their weight lossabout 79 percent of what they had lost on semaglutide and 75 percent of what they'd lost on tirzepatidethan the placebo group."
"People who had been assigned the placebo, meanwhile, maintained about 38 percent of the weight they'd lost on semaglutide and about 49 percent of what they'd lost on tirzepatide. The findings suggest that it is feasible to switch from a"
About one in eight American adults use GLP-1 drugs such as Wegovy and Zepbound for diabetes and weight loss. Many people stop these medications, and most regain weight after discontinuation. Weight regain also commonly follows dieting once the diet ends. Two independent clinical trials published in Nature Medicine tested strategies to prevent regain. One trial followed more than 370 participants who switched after 72 weeks from injectable semaglutide or tirzepatide to a daily oral orforglipron pill or placebo. After about a year, the orforglipron group maintained roughly 79% of semaglutide weight loss and 75% of tirzepatide weight loss, while placebo participants maintained about 38% and 49%, respectively. The results indicate switching to orforglipron may be feasible.
Read at www.scientificamerican.com
Unable to calculate read time
Collection
[
|
...
]